CLC number: R394-3
On-line Access: 2015-03-05
Received: 2014-10-14
Revision Accepted: 2015-01-13
Crosschecked: 2015-02-10
Cited: 2
Clicked: 5561
Wen-biao Chen, Jian-rong Huang, Xiang-qi Yu, Xiao-cong Lin, Yong Dai. Identification of microRNAs and their target genes in Alport syndrome using deep sequencing of iPSCs samples[J]. Journal of Zhejiang University Science B,in press.Frontiers of Information Technology & Electronic Engineering,in press.https://doi.org/10.1631/jzus.B1400272 @article{title="Identification of microRNAs and their target genes in Alport syndrome using deep sequencing of iPSCs samples", %0 Journal Article TY - JOUR
运用高通量测序研究Alport综合征多能干细胞的microRNA及其靶基因目的:寻找来源于Alport综合征患者与正常对照者的多能干细胞差异性表达的microRNA,并对差异性表达的microRNA靶基因进行预测。 创新点:本研究不同于一般的试验标本,试验标本是来源于尿肾脏管细胞诱导而成的多能干细胞。基于Alport综合征是遗传疾病,我们对一遗传家系进行了系统的分析。寻找特异性的差异性表达microRNA及其靶基因,从基因水平对Alport综合征进行研究。 方法:在前期工作中,成功地从实验者与对照者的尿肾脏管细胞诱导成多能干细胞。运用高通量测序技术分析并发现实验者与对照者之间差异性表达的microRNA。对差异性表达的microRNA靶基因进行预测,并进行靶基因聚集分析,研究靶基因主要参与的生物学过程。同时进行靶基因信号传导通路的分析,研究靶基因主要参与的细胞信号传导通路。 结论:在实验组与对照组之间,发现了30个具有显著差异性表达的microRNAs,包括19个上调表达与11个下调表达。差异性表达的microRNA的靶基因主要聚集在细胞膜和细胞代谢过程;靶基因主要参与嘌呤代谢通路与丝裂原活化蛋白激酶(MAPK)通路。 关键词组: Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article
Reference[1]Abrahamson, D.R., Prettyman, A.C., Robert, B., et al., 2003. Laminin-1 reexpression in Alport mouse glomerular basement membranes. Kidney Int., 63(3):826-834. ![]() [2]Abrahamson, D.R., Hudson, B.G., Stroganova, L., et al., 2009. Cellular origins of type IV collagen networks in developing glomeruli. J. Am. Soc. Nephrol., 20(7):1471-1479. ![]() [3]Anders, S., Huber, W., 2010. Differential expression analysis for sequence count data. Genome Biol., 11(10):R106. ![]() [4]Ansorge, W.J., 2009. Next-generation DNA sequencing techniques. N. Biotechnol., 25(4):195-203. ![]() [5]Chen, Y., Luo, R., Xu, Y., et al., 2013. Generation of systemic lupus erythematosus-specific induced pluripotent stem cells from urine. Rheumatol. Int., 33(8):2127-2134. ![]() [6]Chen, Y.H., Wang, S.Q., Wu, X.L., et al., 2013. Characterization of microRNAs expression profiling in one group of Chinese urothelial cell carcinoma identified by Solexa sequencing. Urol. Oncol., 31(2):219-227. ![]() [7]Chung, A.C., Yu, X., Lan, H.Y., 2013. MicroRNA and nephropathy: emerging concepts. Int. J. Nephrol. Renovasc. Dis., 6:169-179. ![]() [8]Colville, D.J., Savige, J., 1997. Alport syndrome. A review of the ocular manifestations. Ophthalmic. Genet., 18(4):161-173. ![]() [9]Dai, Y., Sui, W., Lan, H., et al., 2009. Comprehensive analysis of microRNA expression patterns in renal biopsies of lupus nephritis patients. Rheumatol. Int., 29(7):749-754. ![]() [10]de Luca, A., Maiello, M.R., D'Alessio, A., et al., 2012. The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin. Ther. Targets, 16(S2):S17-S27. ![]() [11]Gehrs, K.M., Pollock, S.C., Zilkha, G., 1995. Clinical features and pathogenesis of Alport retinopathy. Retina, 15(4):305-311. ![]() [12]Gross, O., Beirowski, B., Koepke, M.L., et al., 2003. Preemptive ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome. Kidney Int., 63(2):438-446. ![]() [13]Gross, O., Licht, C., Anders, H.J., et al., 2012. Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy. Kidney Int., 81(5):494-501. ![]() [14]Gubler, M.C., Heidet, L., Antignac, C., 2007. Alport syndrome or progressive hereditary nephritis with hearing loss. Nephrol. Ther., 3(3):113-120 (in French). ![]() [15]Hafner, M., Landgraf, P., Ludwig, J., et al., 2008. Identification of microRNAs and other small regulatory RNAs using cDNA library sequencing. Methods, 44(1):3-12. ![]() [16]He, J., Xu, Y., Koya, D., et al., 2013. Role of the endothelial-to-mesenchymal transition in renal fibrosis of chronic kidney disease. Clin. Exp. Nephrol., 17(4):488-497. ![]() [17]Hertz, J.M., 2009. Alport syndrome. Molecular genetic aspects. Dan. Med. Bull., 56(3):105-152. ![]() [18]Jia, W., Chen, W., Kang, J., 2013. The functions of microRNAs and long non-coding RNAs in embryonic and induced pluripotent stem cells. Genomics Proteomics Bioinformatics, 11(5):275-283. ![]() [19]Jo, D.H., Kim, J.H., Park, W.Y., et al., 2011. Differential profiles of microRNAs in retinoblastoma cell lines of different proliferation and adherence patterns. J. Pediatr. Hematol. Oncol., 33(7):529-533. ![]() [20]Kang, D.H., Nakagawa, T., 2005. Uric acid and chronic renal disease: possible implication of hyperuricemia on progression of renal disease. Semin. Nephrol., 25(1):43-49. ![]() [21]Kashtan, C.E., 1993. Alport syndrome and thin basement membrane nephropathy. In: Pagon, R.A., Adam, M.P., Ardinger, H.H. (Eds.), GeneReviews. University of Washington, Seattle, WA. ![]() [22]Kashtan, C.E., 1999. Alport syndrome: an inherited disorder of renal, ocular, and cochlear basement membranes. Medicine, 78(5):338-360. ![]() [23]Li, R., Yu, C., Li, Y., et al., 2009. SOAP2: an improved ultrafast tool for short read alignment. Bioinformatics, 25(15):1966-1967. ![]() [24]Miner, J.H., 2011. Glomerular basement membrane composition and the filtration barrier. Pediatr. Nephrol., 26(9):1413-1417. ![]() [25]Morozova, O., Marra, M.A., 2008. Applications of next-generation sequencing technologies in functional genomics. Genomics, 92(5):255-264. ![]() [26]Murea, M., 2012. Advanced kidney failure and hyperuricemia. Adv. Chronic Kidney Dis., 19(6):419-424. ![]() [27]O'Connell, S., Tuite, N., Slattery, C., et al., 2012. Cyclosporine A-induced oxidative stress in human renal mesangial cells: a role for ERK1/2 MAPK signaling. Toxicol. Sci., 126(1):101-113. ![]() [28]Pengal, R., Guess, A.J., Agrawal, S., et al., 2011. Inhibition of the protein kinase MK-2 protects podocytes from nephrotic syndrome-related injury. Am. J. Physiol. Renal Physiol., 301(3):F509-F519. ![]() [29]Pfaff, N., Moritz, T., Thum, T., et al., 2012. miRNAs involved in the generation, maintenance, and differentiation of pluripotent cells. J. Mol. Med., 90(7):747-752. ![]() [30]Pohl, M., Danz, K., Gross, O., et al., 2013. Diagnosis of Alport syndrome-search for proteomic biomarkers in body fluids. Pediatr. Nephrol., 28(11):2117-2123. ![]() [31]Punga, T., Le Panse, R., Andersson, M., et al., 2014. Circulating miRNAs in myasthenia gravis: miR-150-5p as a new potential biomarker. Ann. Clin. Transl. Neurol., 1(1):49-58. ![]() [32]Putta, S., Lanting, L., Sun, G., et al., 2012. Inhibiting microRNA-192 ameliorates renal fibrosis in diabetic nephropathy. J. Am. Soc. Nephrol., 23(3):458-469. ![]() [33]Qin, W., Chung, A.C., Huang, X.R., et al., 2011. TGF-β/ Smad3 signaling promotes renal fibrosis by inhibiting miR-29. J. Am. Soc. Nephrol., 22(8):1462-1474. ![]() [34]Steenhard, B.M., Vanacore, R., Friedman, D., et al., 2012. Upregulated expression of integrin α1 in mesangial cells and integrin α3 and vimentin in podocytes of Col4a3-null (Alport) mice. PLoS ONE, 7(12):e50745. ![]() [35]Tan, Y., Ge, G., Pan, T., et al., 2014. A serum microRNA panel as potential biomarkers for hepatocellular carcinoma related with hepatitis B virus. PLoS ONE, 9(9):e107986. ![]() [36]Temme, J., Kramer, A., Jager, K.J., et al., 2012. Outcomes of male patients with Alport syndrome undergoing renal replacement therapy. Clin. J. Am. Soc. Nephrol., 7(12):1969-1976. ![]() [37]Thorner, P.S., 2007. Alport syndrome and thin basement membrane nephropathy. Nephron Clin. Pract., 106(2):c82-c88. ![]() [38]Trionfini, P., Benigni, A., Remuzzi, G., 2015. MicroRNAs in kidney physiology and disease. Nat. Rev. Nephrol., 11(1):23-33. ![]() [39]Tryggvason, K., Zhou, J., Hostikka, S.L., et al., 1993. Molecular genetics of Alport syndrome. Kidney Int., 43(1):38-44. ![]() [40]Zhang, K.W., Colville, D., Tan, R., et al., 2008. The use of ocular abnormalities to diagnose X-linked Alport syndrome in children. Pediatr. Nephrol., 23(8):1245-1250. ![]() [41]Zhang, X., Yan, Z., Zhang, J., et al., 2011. Combination of hsa-miR-375 and hsa-miR-142-5p as a predictor for recurrence risk in gastric cancer patients following surgical resection. Ann. Oncol., 22(10):2257-2266. ![]() Journal of Zhejiang University-SCIENCE, 38 Zheda Road, Hangzhou
310027, China
Tel: +86-571-87952783; E-mail: cjzhang@zju.edu.cn Copyright © 2000 - 2024 Journal of Zhejiang University-SCIENCE |
Open peer comments: Debate/Discuss/Question/Opinion
<1>